Evidence in favour
- Participation spans 6 named insiders rather than one filing source.
Company insider dossier
Nautilus Biotechnology Inc insider intelligence
NAUT filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.
25/100
Concentrated distribution
41/100 confidence- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Latest evidence
- 18 Jun 2026
Investment committee read
Concentrated distribution
Priced common-share disposals are concentrated enough to warrant review, but they are not treated as a standalone bearish forecast.
Review exposure and filing contextDecision risks
- Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
- The latest qualifying filing is more than 30 days old.
Price confirmation map
Weekly price with common-share events
Acquisitions and disposals are aligned to the nearest completed weekly bar.
Feb 2025Aug 2026
Weekly closeCommon-share acquisitionCommon-share disposal
Market confirmation
Price and trend context
- Latest close
- 0.90 USD
- One-week move
- -7.9%
- Four-week move
- -52.4%
- Fair-value gap
- -57.4%
- Trend signal
- Inactive
- Relative strength
- -58.7
Directional balance
Controlled event mix
0.0%acquisition
- Acquisition events
- 0
- Disposal events
- 2
- Net value
- -$11.8M
Cadence
Twelve-week filing pressure
Volume shows attention. Controlled events determine direction.
025 May
201 Jun
008 Jun
515 Jun
022 Jun
029 Jun
006 Jul
013 Jul
020 Jul
027 Jul
003 Aug
010 Aug
Named participants
Insider conviction by person
AKINSANYA, KARENDirector500 events
EPPERLY, MELISSA B,Director500 events
MCILWAIN, MATTHEW SDirector500 events
NAZEM, FARZADDirector500 events
POSARD, MATTHEW L.Director500 events
AH, EQUITY PARTNERS BIO II, L.L.C.10% Owner252 events
Evidence quality
Security and transaction context
Role architecture
Who is participating
Transaction evidence
Auditable NAUT filing ledger
Showing 1 to 7 of 7.
AKINSANYA, KARENDirector
AcquisitionOptions and derivatives
45000 sharesStock Option (Right to Buy)
Not reportedContext evidence
EPPERLY, MELISSA B,Director
AcquisitionOptions and derivatives
45000 sharesStock Option (Right to Buy)
Not reportedContext evidence
MCILWAIN, MATTHEW SDirector
AcquisitionOptions and derivatives
45000 sharesStock Option (Right to Buy)
Not reportedContext evidence
NAZEM, FARZADDirector
AcquisitionOptions and derivatives
45000 sharesStock Option (Right to Buy)
Not reportedContext evidence
POSARD, MATTHEW L.Director
AcquisitionOptions and derivatives
45000 sharesStock Option (Right to Buy)
Not reportedContext evidence
AH, EQUITY PARTNERS BIO II, L.L.C.10% Owner
DisposalCommon equity
4615974 sharesCommon Stock
$10.8MDirectional evidence
AH, EQUITY PARTNERS BIO II, L.L.C.10% Owner
DisposalCommon equity
384026 sharesCommon Stock
$902.5KDirectional evidence
Reading the dossier
Direction and confidence are separate
Conviction
The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.
Confidence
Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.
Disposals
Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.
Price confirmation
The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.
Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.